Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BB 1701

Next Previous
Drug Profile

BB 1701

Alternative Names: BB-1701

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bliss Biopharmaceutical
  • Developer Bliss Biopharmaceutical; Eisai Co Ltd
  • Class 2 ring heterocyclic compounds; Antibodies; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HER2 positive breast cancer; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 30 May 2025 Preliminary efficacy and adverse events data from a phase II trial in Breast cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 19 Feb 2025 BB 1701 is no longer licensed to Bliss Biopharma (Eisai Pipeline, February 2025)
  • 31 Dec 2024 Bliss Biopharmaceuticals completes a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV-infusion) (NCT04257110)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top